SG11201404277WA - Aurora and flt3 kinases modulators - Google Patents

Aurora and flt3 kinases modulators

Info

Publication number
SG11201404277WA
SG11201404277WA SG11201404277WA SG11201404277WA SG11201404277WA SG 11201404277W A SG11201404277W A SG 11201404277WA SG 11201404277W A SG11201404277W A SG 11201404277WA SG 11201404277W A SG11201404277W A SG 11201404277WA SG 11201404277W A SG11201404277W A SG 11201404277WA
Authority
SG
Singapore
Prior art keywords
aurora
flt3 kinases
modulators
kinases modulators
flt3
Prior art date
Application number
SG11201404277WA
Other languages
English (en)
Inventor
John Charles Reader
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of SG11201404277WA publication Critical patent/SG11201404277WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201404277WA 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators SG11201404277WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Publications (1)

Publication Number Publication Date
SG11201404277WA true SG11201404277WA (en) 2014-08-28

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404277WA SG11201404277WA (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Country Status (19)

Country Link
US (1) US9133180B2 (ko)
EP (1) EP2812328B1 (ko)
JP (1) JP6034880B2 (ko)
KR (1) KR102052780B1 (ko)
CN (1) CN104169277B (ko)
AU (1) AU2013218167B2 (ko)
BR (1) BR112014019254B1 (ko)
CA (1) CA2863759C (ko)
DK (1) DK2812328T3 (ko)
ES (1) ES2560260T3 (ko)
GB (1) GB201202027D0 (ko)
HK (1) HK1204327A1 (ko)
IL (1) IL233988A (ko)
MX (1) MX338481B (ko)
PL (1) PL2812328T3 (ko)
PT (1) PT2812328E (ko)
RU (1) RU2643809C2 (ko)
SG (1) SG11201404277WA (ko)
WO (1) WO2013117522A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105903847B (zh) * 2016-06-03 2018-07-27 苏州赛腾精密电子股份有限公司 一种o型密封圈成形机构
MX2020001531A (es) * 2017-08-07 2020-03-20 Biocad Joint Stock Co Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
CA2422617C (en) 2000-10-30 2011-07-12 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
AU2003902208A0 (en) * 2003-05-08 2003-05-22 Fujisawa Pharmaceutical Co., Ltd. Inhibitor of cox
BRPI0415467A (pt) 2003-10-23 2006-12-19 Ab Science compostos de 2-aminoariloxazol para o tratamento de doenças
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
DE602007009085D1 (de) 2006-05-12 2010-10-21 Ab Science Neues verfahren zur synthese von 2-aminooxazolverbindungen
US20090093452A1 (en) * 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP2011518221A (ja) 2008-04-21 2011-06-23 メルク・シャープ・エンド・ドーム・コーポレイション Janusキナーゼの阻害剤
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
US8962665B2 (en) * 2010-01-12 2015-02-24 Ab Science Thiazole and oxazole kinase inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
DK3040336T3 (da) 2012-03-02 2020-06-22 Sareum Ltd Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande

Also Published As

Publication number Publication date
CA2863759A1 (en) 2013-08-15
WO2013117522A1 (en) 2013-08-15
CA2863759C (en) 2020-04-14
IL233988A (en) 2017-06-29
MX338481B (es) 2016-04-19
EP2812328B1 (en) 2015-11-18
BR112014019254B1 (pt) 2020-03-10
ES2560260T3 (es) 2016-02-18
KR102052780B1 (ko) 2019-12-05
KR20140128373A (ko) 2014-11-05
GB201202027D0 (en) 2012-03-21
RU2643809C2 (ru) 2018-02-06
PL2812328T3 (pl) 2016-04-29
BR112014019254A8 (pt) 2017-07-11
EP2812328A1 (en) 2014-12-17
MX2014009323A (es) 2015-04-08
JP6034880B2 (ja) 2016-11-30
AU2013218167B2 (en) 2017-04-06
RU2014131784A (ru) 2016-03-27
CN104169277B (zh) 2016-10-12
CN104169277A (zh) 2014-11-26
DK2812328T3 (en) 2016-01-11
PT2812328E (pt) 2016-03-01
US20150018367A1 (en) 2015-01-15
JP2015511228A (ja) 2015-04-16
US9133180B2 (en) 2015-09-15
BR112014019254A2 (ko) 2017-06-20
HK1204327A1 (en) 2015-11-13
AU2013218167A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
IL262110A (en) dll3 modulators and methods to use
HK1216322A1 (zh) 組糖基轉移酶及其應用
IL245733A0 (en) aplnr modulators and their uses
EP2925822A4 (en) INKS BASED ON BIOPOLYMERS AND THEIR USE
HK1206666A1 (en) Phototherapy devices and methods
EP2908780A4 (en) ALIGNMENT DEVICES AND METHODS
HK1203493A1 (en) Substituted azabicycles and use thereof
HK1201199A1 (en) Methods of using fgf19 modulators fgf19
EP2844247A4 (en) ROR MODULATORS AND ITS USES
EP2902475A4 (en) CELL CULTURAL VESSEL AND CELL CULTURE DEVICE WITH IT
HK1206017A1 (en) Complement pathway modulators and uses thereof
IL240929A0 (en) 7- Converted azabicycles and their use as orexin receptor modulators
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
EP2927256A4 (en) URETHANE TYPE POLYMER AND USE THEREOF
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
EP2844260A4 (en) ROR MODULATORS AND ITS USES
EP2909181A4 (en) PKM2 MODULATORS AND METHODS OF USING SAME
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
HK1204327A1 (en) Aurora and flt3 kinases modulators flt3
EP2895474A4 (en) LEGIBLE MODULATORS AND METHOD OF USE THEREFOR
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder